IL-2 and GLP-1 receptor agonist combination tackles neuroinflammation
Can targeting both regulatory and inflammatory pathways change how we…
Can targeting both regulatory and inflammatory pathways change how we treat neurodegenerative disease? Coya Therapeutics is testing that idea with its IL-2 and GLP-1 receptor agonist combination.




